Valganciclovir/Valcyte launch date

Valganciclovir/Valcytein 20015 month Approved for marketing by the FDA in the United States, it was launched in the European Union in 2003 and in China in 2005. Valganciclovir is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS). Valganciclovir is indicated for the prevention of high-risk kidney, heart and kidney-pancreas transplant patientsCMV disease(donor< span>CMVSeropositive/ReceptorCMVSeronegative[D+/R-]).

Based on animal data and limited human data, Valganciclovir may temporarily or permanently inhibit spermatogenesis in males and may inhibit fertility in females at recommended human doses. Inform patients that use of valganciclovir may impair fertility.

Animal studies have found that valganciclovir may cause fetal toxicity when taken by pregnant women. When administered to pregnant rabbits at doses that resulted in 2 times the human exposure (based on AUC) , valganciclovir caused fetal malformations of multiple organs. Maternal and fetal toxicity has also been observed in pregnant mice and rabbits. Therefore,valganciclovirhas the potential to cause birth defects. Female patients takingvalganciclovir and women whose male partners are takingvalganciclovir should avoid becoming pregnant. Given the potential risk to the fetus, females of reproductive potential should be advised to use effective contraception during treatment and for at least 30days following treatment with valganciclovir. Likewise, men should be advised to use condomsduring valganciclovirtreatment and for at least 90days after treatment. The retail price of the Turkish version of the original drug in pharmacies is 0.45g*60tablets2 more than a thousand. Indian original drug pharmacy retail price0.45g*60pieces4about one thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.